Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

171

P173 Six-minute Walk Test Heart Rate Variability in Pulmonary Arterial Hypertension/ S. Rusnak, Rochester, NY P174 Hemodynamic Predictors of Mortality in Pulmonary Hypertension, a Secondary Data Analysis/ A.G. Shepherd, Atlanta, GA P175 Correlation of WHO Functional Class and Patient-Reported Outcome Measures in Adults With Pulmonary Arterial Hypertension/ K. El-Kersh, Omaha, NE P176 Home 6-Minute Walk Using Wearable Sensors/ D. Lachant, Rochester, NY P177 Activity Does Not Increase After Adding Vasodilators in Pulmonary Arterial Hypertension/ D. Lachant, Rochester, NY P178 Physical Activity Characteristics in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR)/ M. Batson, Philadelphia, PA P179 Older Patients With Pulmonary Hypertension Have Transplant-free Survival Compared to Non-Hispanics at a Tertiary Referral Academic Pulmonary Hypertension Center in South Texas/ R.A. Estrada, San Antonio, TX P181 Biopsychosocial and Economic Impact in Patients With Pulmonary Arterial Hypertension: Treatable Traits/ B. Esper Baptista Da Costa, Goiânia, Brazil P182 Vasodilator Therapy Does Not Change Heart Rate Variability in Pulmonary Arterial Hypertension/ B. Gyawali, Rochester, NY P183 Pulmonary Artery Pulsatility Index Is Associated With Pericardial Effusion in Patients With Systemic Sclerosis-related Pulmonary Hypertension/ J. Vakhshoorzadeh, Boston, MA P184 Non-invasive Evaluation of Oxygen Deficit in Pulmonary Vascular Disease/ N. Patel, Los Angeles, CA P185 Candidemia as a Risk Factor for Pulmonary Hemorrhage in Adults: A Preliminary Observation/ N. Khouzam, Chicago, IL P186 Gender Difference in Pulmonary Arterial Hypertension/ J. Gatuz, Shreveport, LA P187 Determinants of Right Ventricular Failure in Pulmonary Hypertension Type 1/ K. El Gharib, New York, NY P188 Cardiac Output Assessment by Thoracic Bio-reactance for the Follow-up of Patients With Pulmonary Hypertension Phreact Study/ S. Turquier, Bron, France Comparable Transplant-free Survival to Younger Patients at a Tertiary Referral Academic Pulmonary Hypertension Center/ R.A. Estrada, San Antonio, TX P180 Patients With Hispanic Ethnicity Have Similar

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

B57

INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P161 Win Ratio Analysis of the FREEDOM-EV Trial - a Hierarchical Approach to Multiple Clinical Endpoints/ R.J. White, Rochester, NY P162 Impact of Body Position on Hemodynamic Measurements During Exercise: A Tale of Two Bikes/ P. Kirupaharan, Philadelphia, PA P163 Worth “Weighting”: A Single-center Cohort Study of Current and Historical Weight in Pulmonary Arterial Hypertension/ L.J. Oppegard, Portland, OR P164 D-dimer and Angiopoietin-2 Are Markers of Hospitalization-free Survival and Treatment Response in Pulmonary Hypertension/ H. Clark, Rochester, NY P165 Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH)/ C. Durrington, Sheffield, United Kingdom P166 Changes in Human Neutrophil Elastase May Impact Pulmonary Vascular Reactivity in People With PAH/ C.J. Dennis, Stanford, CA P167 Frailty and Body Composition in Patients With Pulmonary Arterial Hypertension/ M. Prakash, Philadelphia, PA P168 Assessing the Correlation Between Actigraphy Data and Clinical Measures: Insights From the Adapt Registry/ J. Gagermeier, Maywood, IL P169 Pilot Study of a Novel Biosensor Device in Pulmonary Arterial Hypertension/ J. Hsieh, Philadelphia, PA P170 Association of Cerebrovascular Remodeling With Chronic Pulmonary Vascular Remodeling; Is Uric Acid the Missing Link?/ M.A. Fini, Aurora, CO P171 Relationship Between Hepatic Fat Content and Pulmonary Vascular Disease Severity in a Subset of the Pvdomics Cohort/ B.E. Funke, Nashville, TN P172 Role of Genetic Testing in Pulmonary Arterial Hypertension Evaluation: A Patient and Clinician Survey/ J. Rice, Denver, CO

ATS 2023 • Washington, DC